cagrilintide and tirzepatide together Beyond semaglutide tirzepatide, where might we find the next GLP-1-based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of + semaglutide and Novo Nordisk's CagriSema Shows Strong

Notably, Epitalon appears to selectively induce apoptosis in cancer cells without harming normal, healthy tissue, indicating its potential as a targeted anti-cancer therapy

Legal battle involving peptide restrictions The backstory: A legal challenge spearheaded by EVEXIAS Life Sciences is actively fighting the FDA's placement of 17 peptides on its restrictive "Category 2" list, which effectively bans compounding pharmacies from making them under the claim that they are unsafe

What stood out: CagriSema achieved 23.0% weight loss at 84 weeks (efficacy estimand) Tirzepatide achieved 25.5% On the treatment-regimen estimand, weight loss was 20.2% vs 23.6% Primary endpoint not met: CagriSema did not demonstrate non-inferiority vs tirzepatide on weight loss at 84 weeks Why this matters This is a reminder that in obesity pharmacotherapy, very effective and best-in-class are not the same conversation

With simultaneous occlusion of both superior mesenteric vessels, i.e., the artery and the vein, both pathways, arterial and venous, are activated (Knezevic et al., 2021a)